The group's principal activity is application of proprietary genomics technologies in the early detection of colorectal cancer and other types of common cancers. Pregen-plus utilizes pregen technologies to isolate the minute amounts of human dna shed from the colon into stool and then identifies mutations in dna shed from abnormal cells indicative of colorectal cancer and pre-cancerous lesions. The group's technology platform consists of the proprietary cancer detection methods such as multiple mutation detection (mumu (r)), deletion technology, dna integrity assay (dia) and enumerated loss of heterozygosity (e-loh).
